Drug intelligence / Profile preview

Brekiya

Development stage: Approved
Lead developer: Amneal Pharmaceuticals
Modality: Small Molecules
Administration: Subcutaneous

Overview

Brekiya is an autoinjector developed by Amneal Pharmaceuticals that delivers dihydroergotamine mesylate (DHE) for the acute treatment of migraine (with or without aura) and cluster headaches in adults. It is the first and only DHE autoinjector, providing a ready-to-use, self-administered subcutaneous injection. DHE works by binding to 5-HT1Dα and 5-HT1Dβ receptors, causing vasoconstriction of cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides.

Brand names: Brekiya

Targets

HTR1D (5-hydroxytryptamine receptor 1D)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HTR2C (5-hydroxytryptamine 2C receptor)ADRA2A (α2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on Brekiya.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brekiya.

Explore the full profile